References 576% CONFIDENCEOverall confidence: 76%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]90%gsk.com/en-gb/media/press-releases/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myelomagsk.com· Posted Oct 4, 2026· Starts Oct 23, 2025 ✓· 23% of score
GSK's press release states the FDA approval; the 23 October 2025 date is given by Pharmaceutical Executive's 24 October article and by a search summary of GSK's announcement, and the PharmaLetter[4] calls it a re-approval.
- [2]70%Belantamab mafodotin - Wikipedia
Gives the 2020 approval and 2022 withdrawal history.[1]
- [3]75%U.S. FDA Approves Blenrep for the Treatment of Relapsed/Refractory Multiple Myeloma - International Myeloma Foundationmyeloma.org· Added Oct 4, 2026· 23% of score
Patient-organisation report of the approval.[1]
- [4]70%Blenrep re-approved by FDA for relapsed/refractory multiple myeloma - The Pharma Letterthepharmaletter.com· Added Oct 4, 2026· 23% of score
Trade report describing a re-approval.[1]
- [5]75%FDA Approves Blenrep for Treatment of Relapsed/Refractory Multiple Myeloma - Pharmaceutical Executivepharmexec.com· Published Oct 24, 2025· 6% of score
Trade-press report, 24 October 2025.[1]
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most. A picture that shows something else, or shows it badly, is looked at too, and moved down or replaced.